Mission Fulphila - Mylan-Biocon Biosimilar Neulasta Takes The Stage In US
Executive Summary
The first FDA-approved Neulasta biosimilar is here, opening up material earnings opportunities for partners Mylan and Biocon and affirming the duo's ability to deliver on their complex but high-value pipeline.
You may also be interested in...
Pharma Q2 Results Preview: Celgene, Amgen, Allergan And AbbVie
With the FDA updating its stance on interchangeability, analysts will be pushing Amgen and AbbVie on how the policy changes will affect biosimilar competition. Celgene and Allergan will be under pressure for R&D updates; Allergan remains in the hot seat on its pipeline growth strategy from activist investors.
Pharma Q2 Results Preview: Celgene, Amgen, Allergan And AbbVie
With the FDA updating its stance on interchangeability, analysts will be pushing Amgen and AbbVie on how the policy changes will affect biosimilar competition. Celgene and Allergan will be under pressure for R&D updates; Allergan remains in the hot seat on its pipeline growth strategy from activist investors.
Mylan's Fulphila Approval: Lack Of US FDA AdComm May Be A Positive For Biosimilar Industry
The advisory committee route for approving a first biosimilar to a reference product is no longer necessarily the norm, going by FDA's recent approval of Mylan/Biocon's pegfilgrastim-jmdb, which references Amgen’s Neulasta; agency’s view that a meeting was not needed should encourage other biosimilar aspirants.